Search Results - "Braghiroli, Maria Ignez"

Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center by Silva, Andrea C.B., Vicentini, Maria Fernanda B., Mendoza, Elizabeth Z., Fujiki, Fernanda K., da Fonseca, Leonardo G., Braghiroli, Maria Ignez F.M., Hoff, Paulo M.

“…There is an apparent increasing incidence of colorectal cancer among young people observed in daily practice and database studies. We did a retrospective…”
Get full text

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib by da Fonseca, Leonardo Gomes, Marta, Guilherme Nader, Braghiroli, Maria Ignez Freitas Melro, Chagas, Aline Lopes, Carrilho, Flair Jose, Hoff, Paulo Marcelo, Sabbaga, Jorge

“…Before the targeted therapies era, cytotoxic chemotherapy (CCT) was an option for advanced hepatocellular carcinoma (HCC), even with the lack of supporting…”
Get full text

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations by Cercek, Andrea, Braghiroli, Maria Ignez, Chou, Joanne F, Hechtman, Jaclyn F, Kemeny, Nancy, Saltz, Leonard, Capanu, Marinela, Yaeger, Rona

“…mutations are now routinely included in RAS testing prior to EGFR inhibitor therapy for metastatic colorectal cancer (mCRC). The clinical implications of…”
Get full text

Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer by de M Rêgo, Juliana Florinda, de Medeiros, Raphael Salles Scortegagna, Braghiroli, Maria Ignez, Galvão, Breno, Neto, João Evangelista Bezerra, Munhoz, Rodrigo Ramella, Guerra, Juliana, Nonogaki, Suely, Kimura, Lidia, Pfiffer, Tulio Eduardo, de Castro, Jr, Gilberto, Hoff, Paulo Marcelo, Filho, Duilio Rocha, Costa, Frederico Perego, Riechelmann, Rachel P

“…Small cell lung cancer (SCLC) and high-grade extrapulmonary neuroendocrine carcinomas (EPNEC) share similar histopathological features and treatment, but…”
Get full text

Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? by Fernandes, Gustavo S., Marques, Daniel F., Girardi, Daniel M., Braghiroli, Maria Ignez F., Coudry, Renata A., Meireles, Sibele I., Katz, Artur, Hoff, Paulo M.

“…With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to…”
Get full text

Primary prevention of colorectal cancer:Myth or reality? by Crosara Teixeira, Marcela, Braghiroli, Maria Ignez, Sabbaga, Jorge, Hoff, Paulo M

“…Colorectal cancer incidence has been rising strongly in parallel with economic development.In the past few decades,much has been learned about the…”
Get full text

Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas by Ramella Munhoz, Rodrigo, de Mendonça Rego, Juliana Florinda, de Celis Ferrari, Anezka Rubim, Ignez Braghiroli, Maria, Mendonça Bariani, Giovanni, Marcelo Hoff, Paulo, Perego Costa, Frederico, Eduardo Flesch Pfiffer, Túlio, Riechelmann, Rachel

“…Extrapulmonary poorly differentiated neuroendocrine carcinoma (PDNEC) is a rare and highly aggressive neoplasm for which the optimal chemotherapy remains…”
Get full text

Is There a Role for Locoregional Therapies for Non-colorectal Gastrointestinal Malignancies? by Fonseca, Gilton Marques, Braghiroli, Maria Ignez Freitas Melro, Pirola Kruger, Jaime Arthur, Coelho, Fabricio Ferreira, Herman, Paulo

“…The liver is the most common site of metastases from solid gastrointestinal tract tumors. Over the past few decades, the role of locoregional therapies,…”
Get full text

Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma by Marta, Guilherme Nader, da Fonseca, Leonardo G., Braghiroli, Maria Ignez, Moura, Fernando, Hoff, Paulo M., Sabbaga, Jorge

“…To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC). We analyzed data from a cohort of patients…”
Get full text

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial by Kato, Ken, Doki, Yuichiro, Chau, Ian, Xu, Jianming, Wyrwicz, Lucjan, Motoyama, Satoru, Ogata, Takashi, Kawakami, Hisato, Hsu, Chih‐Hung, Adenis, Antoine, El Hajbi, Farid, Di Bartolomeo, Maria, Braghiroli, Maria Ignez, Holtved, Eva, Makino, Tomoki, Blum Murphy, Mariela, Amaya‐Chanaga, Carlos, Patel, Apurva, Hu, Nan, Matsumura, Yasuhiro, Kitagawa, Yuko, Ajani, Jaffer

“…Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy…”
Get full text

Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer by Janjigian, Yelena Y., MD, Braghiroli, Maria Ignez, MD

“…Esophagogastric cancer is a worldwide health problem. The addition of the epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab to…”
Get full text

Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies by Nishimuni, Marina, Claro, Laura Carolina Lopez, Braghiroli, Maria Ignez Freitas Melro

“…Abstract Gastric cancer is the fifth most common cause of cancer-related deaths globally, with a decreasing but still high number of cases. Although there have…”
Get full text

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study by Chau, Ian, Doki, Yuichiro, Ajani, Jaffer A., Xu, Jianming, Wyrwicz, Lucjan, Motoyama, Satoru, Ogata, Takashi, Kawakami, Hisato, Hsu, Chih-Hung, Adenis, Antoine, El Hajbi, Farid, Di Bartolomeo, Maria, Braghiroli, Maria Ignez Freitas Melro, Holtved, Eva, Xynos, Ioannis, Liu, Xuan, Lei, Ming, Kondo, Kaoru, Kato, Ken, Kitagawa, Yuko

“…Abstract only LBA4001 Background: NIVO demonstrated superior overall survival (OS) vs chemo in previously treated patients (pts) with ESCC (ATTRACTION-3). We…”
Get full text

Unveiling the Landscape of Brazilian Clinical Oncologists: Challenges, Diversity, and Quality Care by Bezerra, Sarah Mendes, Madi, Marisa Riscalla, Chaves, Aline Lauda Freitas, Melro-Braghiroli, Maria Ignez Freitas, Hoff, Paulo Marcelo Gehm, Ferreira, Carlos Gil, Bonanno, Lucas Pondaco, Leite, Gustavo Andrade Pimenta

“…Abstract Cancer remains a significant public health challenge in Brazil, with an estimated 704 thousand new cases annually. Clinical oncology, a pivotal…”
Get full text

BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA by Chagas, Aline Lopes, Mattos, Angelo Alves de, Carrilho, Flair José, Bittencourt, Paulo Lisboa, Vezozzo, Denise Cerqueira Paranaguá, Horvat, Natally, Rocha, Manoel de Souza, Alves, Venâncio Avancini Ferreira, Coral, Gabriela Perdomo, Alvares-DA-Silva, Mario Reis, Barros, Fabio Marinho do Rego, Menezes, Marcos Roberto, Monsignore, Lucas Moretti, Coelho, Fabricio Ferreira, Silva, Renato Ferreira da, Silva, Rita de Cássia Martins Alves, Boin, Ilka de Fatima Santana Ferreira, D Albuquerque, Luiz Augusto Carneiro, Garcia, José Huygens Parente, Felga, Guilherme Eduardo Gonçalves, Moreira, Airton Mota, Braghiroli, Maria Ignez Freitas Melro, Hoff, Paulo Marcelo Gehm, Mello, Vivianne Barretto de, Dottori, Mariana Fonseca, Branco, Tiago Pugliese, Schiavon, Leonardo de Lucca, Costa, Thaisa de Fátima Almeida

“…Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2015…”
Get full text

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial by Shitara, Kohei, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles, Wyrwicz, Lucjan, Lee, Keun-Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Lee, Jeeyun, Castro, Hugo Raul, Mansoor, Wasat, Braghiroli, Maria Ignez, Karaseva, Nina, Caglevic, Christian, Villanueva, Luis, Goekkurt, Eray, Satake, Hironaga, Enzinger, Peter, Alsina, Maria, Benson, Al, Chao, Joseph, Ko, Andrew H, Wainberg, Zev A, Kher, Uma, Shah, Sukrut, Kang, S Peter, Tabernero, Josep

“…Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. To evaluate the antitumor activity…”
Get more information

The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment by Connell, Louise C., Mota, José Mauricio, Braghiroli, Maria Ignez, Hoff, Paulo M.

“…Opinion statement Colorectal cancer (CRC) is the third leading cancer diagnosed globally and an important cause of cancer-related mortality. Of interest, while…”
Get full text

Is There a Role for Locoregional Therapies for Non-colorectal Gastrointestinal Malignancies? by Fonseca, Gilton Marques, Braghiroli, Maria Ignez Freitas Melro, Pirola Kruger, Jaime Arthur, Coelho, Fabricio Ferreira, Herman, Paulo

“…The liver is the most common site of metastases from solid gastrointestinal tract tumors. Over the past few decades, the role of locoregional therapies,…”
Get full text

Cisplatin and capecitabine as definitive chemoradiation for squamous cell carcinoma of the anal canal (SCCAC): A prospective cohort by Dornellas, Abraão, Bonadio, Renata Colombo, Moraes, Priscila Muniz, Galhera, Denis, Victor, Carolina Ribeiro, Chen, Andre Tsin Chih, Muratori, Carolina Teixeira, Ortega, Cinthia, Alves, Henrique Souza, Ibrahim, Karim, Nahas, Caio, Marques, Carlos Frederico, Alban, Luciana Bastos Valente, Braghiroli, Maria Ignez, Hoff, Paulo Marcelo, Venchiarutti Moniz, Camila M

“…e15503 Background: SCCAC is a rare disease. The standard of care treatment with curative intent is chemoradiation (CRT) with mitomycin (MMC) or cisplatin…”
Get full text

Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648 by Lei, Ming, Doki, Yuichiro, Kitagawa, Yuko, Kato, Ken, Chau, Ian, Yao, Jin, Xu, Jianming, Wyrwicz, Lucjan S., Motoyama, Satoru, Ogata, Takashi, Kawakami, Hisato, Hsu, Chih-Hung, Adenis, Antoine, El Hajbi, Farid, Di Bartolomeo, Maria, Braghiroli, Maria Ignez, Holtved, Eva, Blum Murphy, Mariela A., Novosiadly, Ruslan, Ajani, Jaffer A.

“…252 Background: NIVO + chemo and NIVO + IPI demonstrated superior overall survival (OS) vs chemo in previously untreated patients with advanced ESCC in…”
Get full text